CN111386115A - 用于治疗非酒精性脂肪性肝炎的方法和药物组合物 - Google Patents

用于治疗非酒精性脂肪性肝炎的方法和药物组合物 Download PDF

Info

Publication number
CN111386115A
CN111386115A CN201880076561.6A CN201880076561A CN111386115A CN 111386115 A CN111386115 A CN 111386115A CN 201880076561 A CN201880076561 A CN 201880076561A CN 111386115 A CN111386115 A CN 111386115A
Authority
CN
China
Prior art keywords
pirfenidone
administered
ubenimex
nash
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880076561.6A
Other languages
English (en)
Chinese (zh)
Inventor
大卫·克里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiger Biopharmaceuticals Inc
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of CN111386115A publication Critical patent/CN111386115A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880076561.6A 2017-11-28 2018-11-27 用于治疗非酒精性脂肪性肝炎的方法和药物组合物 Pending CN111386115A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762591667P 2017-11-28 2017-11-28
US62/591,667 2017-11-28
PCT/US2018/062645 WO2019108551A1 (en) 2017-11-28 2018-11-27 Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
CN111386115A true CN111386115A (zh) 2020-07-07

Family

ID=66664242

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880076561.6A Pending CN111386115A (zh) 2017-11-28 2018-11-27 用于治疗非酒精性脂肪性肝炎的方法和药物组合物

Country Status (7)

Country Link
US (1) US20210369693A1 (https=)
EP (1) EP3716975A4 (https=)
JP (1) JP2021504479A (https=)
CN (1) CN111386115A (https=)
AU (1) AU2018375298A1 (https=)
CA (1) CA3082178A1 (https=)
WO (1) WO2019108551A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518918A4 (en) 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
WO2023220003A1 (en) * 2022-05-10 2023-11-16 Opko Pharmaceuticals, Llc Topical ophthalmic pirfenidone-loaded liposomes to increase the therapeutic activity of the drug in cornea and useful for prevention or therapy of corneal haze
CN118680879A (zh) * 2024-06-03 2024-09-24 贵州医科大学 一种用于负载吡非尼酮的口服肝靶向纳米乳剂及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US20130251787A1 (en) * 2012-03-23 2013-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of Pulmonary Hypertension with Leukotriene Inhibitors
CN104780762A (zh) * 2012-08-31 2015-07-15 英特姆尼国际公司 施用吡非尼酮疗法的方法
TW201725202A (zh) * 2015-12-22 2017-07-16 拜耳製藥公司 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1098249C (zh) * 1995-06-21 2003-01-08 国家医药管理局四川抗菌素工业研究所 乌比美克及含乌比美克的药物组合物治疗病毒性肝炎的用途
WO2001058448A1 (fr) * 2000-02-09 2001-08-16 Shionogi & Co., Ltd. Inhibiteur d'apoptose
AU2016348638A1 (en) * 2015-11-06 2018-06-07 Gemphire Therapeutics Inc. Gemcabene combinations for the treatment of cardiovascular disease
EP3518918A4 (en) * 2016-09-28 2020-04-22 Eiger Biopharmaceuticals, Inc. METHOD AND PHARMACEUTICAL COMPOSITIONS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS
MX364040B (es) * 2016-11-11 2019-04-11 Cell Therapy And Tech S A De C V Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US20130251787A1 (en) * 2012-03-23 2013-09-26 The Board Of Trustees Of The Leland Stanford Junior University Treatment of Pulmonary Hypertension with Leukotriene Inhibitors
CN104780762A (zh) * 2012-08-31 2015-07-15 英特姆尼国际公司 施用吡非尼酮疗法的方法
TW201725202A (zh) * 2015-12-22 2017-07-16 拜耳製藥公司 新穎經取代吲唑、其製法、包含其之醫藥製劑及其製備藥劑之用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIKARA KOMIYA.ETAL: "Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis", 《NATURE》 *
MARCOS MARTI ́NEZ-CLEMENTE ETAL: "The 5-lipoxygenase/leukotriene pathway in obesity, insulinresistance, and fatty liver disease", 《GENES AND CELL METABOLISM》 *
李丽莎等: "白三烯B4在"肺保护性"通气致肺损伤中的作用机制", 《南方医科大学学报》 *

Also Published As

Publication number Publication date
US20210369693A1 (en) 2021-12-02
EP3716975A4 (en) 2022-01-12
JP2021504479A (ja) 2021-02-15
CA3082178A1 (en) 2019-06-06
WO2019108551A1 (en) 2019-06-06
AU2018375298A1 (en) 2020-05-28
EP3716975A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
US11179359B2 (en) Treatment of NAFLD and NASH
CN109862888B (zh) 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
CN111386115A (zh) 用于治疗非酒精性脂肪性肝炎的方法和药物组合物
CN111093705A (zh) 包含fxr激动剂的组合
TW202313010A (zh) 治療粒線體相關病症之方法
BRPI0707670A2 (pt) composiÇço farmacÊutica, e, uso de um composto meglitinida
EP4475841A1 (en) Methods of weight loss and preserving skeletal muscle mass
WO2019099509A1 (en) Use of a p2x7 receptor antagonist to treat an inflammatory disease or disorder
TW202210081A (zh) 非酒精性脂肪肝炎（ｎａｓｈ）之治療
US20250134865A1 (en) Methods of weight loss in a subject with elevated hba1c
KR20260021653A (ko) IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄
HK40089720A (zh) 非酒精性脂肪性肝炎(nash)的治疗
HK40089967A (zh) 非酒精性脂肪性肝炎(nash)的治疗
CN118900692A (zh) HbA1c升高的受试者的体重减轻方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200707